Ligand director granted RSUs and options
Ligand Pharmaceuticals director John W. Kozarich received new equity awards as part of his board compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Ligand Pharmaceuticals director John W. Kozarich received new equity awards as part of his board compensation. On June 5, 2026, he was granted 836 restricted stock units, each representing one share of common stock, and a non-qualified stock option for 2,938 shares at an exercise price of $237.00 per share. Both awards fully vest on the earlier of the company’s next annual stockholder meeting following the grant date or the first anniversary of the grant date. Following these grants, Kozarich directly holds 42,622 shares of Ligand common stock.
Insider Trade Summary
Grant/Award: 3,774 shares
Grant/Award
2 txns
Insider
KOZARICH JOHN W
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (right to buy) | 2,938 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 836 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 2,938 contracts (Direct);
Common Stock — 42,622 shares (Direct)
Footnotes (2)
- F1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
- F2. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
Key Figures
Restricted stock units granted: 836 RSUs
Options granted: 2,938 options
Option exercise price: $237.00 per share
+2 more
5 metrics
Restricted stock units granted
836 RSUs
Equity grant on June 5, 2026
Options granted
2,938 options
Non-qualified stock option grant on June 5, 2026
Option exercise price
$237.00 per share
Non-qualified stock option for common stock
Shares underlying options
2,938 shares
Underlying common stock for new option grant
Shares held after transaction
42,622 shares
Direct common stock holdings after June 5, 2026 grants
Key Terms
restricted stock units ("RSUs"), Non-Qualified Stock Option, exercise price, annual meeting of the Company stockholders, +1 more
5 terms
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy) with an exercise price of 237.0000"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
exercise price financial
"Non-Qualified Stock Option (right to buy) with an exercise price of 237.0000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
annual meeting of the Company stockholders regulatory
"Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders"
contingent right financial
"Each RSU represents a contingent right to receive one share of the Issuer's common stock"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Ligand Pharmaceuticals (LGND) director John W. Kozarich receive in this Form 4?
John W. Kozarich received equity compensation consisting of restricted stock units and stock options. The filing shows 836 RSUs and a non-qualified stock option for 2,938 shares, reflecting routine board compensation rather than an open-market stock purchase or sale.
What is the exercise price of John W. Kozarich’s new Ligand (LGND) stock options?
The newly granted non-qualified stock options have an exercise price of $237.00 per share. This means Kozarich can buy Ligand common stock at that fixed price upon vesting and exercise, subject to the option’s expiration date and plan conditions.
When do John W. Kozarich’s new Ligand (LGND) RSUs and options vest?
Both the RSUs and the stock options fully vest on the earlier of two events. They vest at the next annual meeting of Ligand stockholders following June 5, 2026, or on the first anniversary of the June 5, 2026 grant date, whichever occurs first.
Are John W. Kozarich’s Ligand (LGND) awards open-market purchases or sales?
The awards are grants from Ligand’s board, not open-market trades. The Form 4 uses transaction code “A,” indicating a grant or award, with no reported open-market buying or selling activity by Kozarich on the June 5, 2026 transaction date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
